Vanda Pharmaceuticals (NASDAQ:VNDA) Issues Earnings Results

Vanda Pharmaceuticals (NASDAQ:VNDA) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13), Zacks reports. The firm had revenue of $51.72 million during the quarter, compared to analysts’ expectations of $54.98 million. Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 23.85%.

Here are the key takeaways from Vanda Pharmaceuticals’ conference call:

• Fanapt showed strong commercial momentum with Q1 net sales of $29.6M, TRX up 32% and NBRx up 76% year‑over‑year, and weekly TRX hit an 11‑year high of >2,600 in April.
• Vanda launched NEREUS via a direct‑to‑consumer platform (nereus.us), received FDA approval for BYSANTI (milsaperidone), and had a BLA accepted for imsidolimab with an FDA action date of Dec 12, 2026 (pivotal data published in NEJM Evidence).
• Q1 revenue was modestly higher at $51.7M (+3% YoY) but Vanda reported a net loss of $48.6M, operating expenses rose ~ $10.8M due to commercial and launch spending, cash fell to $202.3M, and management warned 2026 cash burn will likely exceed 2025.
• Vanda raised full‑year 2026 revenue guidance to $240M–$290M (midpoint $265M, ~23% growth vs. 2025), including an inaugural NEREUS sales range of $10M–$30M and Fanapt guidance of $150M–$170M.

Vanda Pharmaceuticals Stock Performance

VNDA opened at $7.44 on Thursday. Vanda Pharmaceuticals has a twelve month low of $3.81 and a twelve month high of $9.94. The firm has a market capitalization of $447.40 million, a PE ratio of -1.99 and a beta of 0.65. The company has a current ratio of 2.39, a quick ratio of 2.38 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $7.60 and its 200 day moving average price is $6.79.

Analyst Ratings Changes

A number of research firms have recently commented on VNDA. Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Monday, April 20th. Truist Financial initiated coverage on Vanda Pharmaceuticals in a report on Thursday, March 5th. They issued a “buy” rating and a $18.00 price objective on the stock. Zacks Research downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 18th. Finally, HC Wainwright increased their target price on Vanda Pharmaceuticals from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Vanda Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $14.90.

Insider Buying and Selling

In other Vanda Pharmaceuticals news, SVP Timothy Williams sold 42,434 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $8.27, for a total value of $350,929.18. Following the transaction, the senior vice president directly owned 377,450 shares of the company’s stock, valued at $3,121,511.50. This trade represents a 10.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Kevin Patrick Moran sold 42,442 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $8.27, for a total value of $350,995.34. Following the completion of the sale, the chief financial officer owned 411,380 shares of the company’s stock, valued at $3,402,112.60. This trade represents a 9.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 314,342 shares of company stock worth $2,583,985 in the last 90 days. Corporate insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. raised its stake in Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 5,328 shares during the period. Jain Global LLC purchased a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at approximately $94,000. Quarry LP purchased a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter valued at approximately $53,000. Boothbay Fund Management LLC purchased a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter valued at approximately $72,000. Finally, Cerity Partners LLC purchased a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter valued at approximately $69,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.